Survivin rs9904341 (G>C) polymorphism contributes to cancer risk: An updated meta-analysis of 26 studies

Tumor Biology

Volumn 35, Issue 2, 2014, Pages 1661-1669

  Xu, Lei ^a   Zhou, Xin ^a   Xu, Lin ^a   Yin, Rong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cancer risk; Genetic polymorphism; Meta analysis; Survivin

Indexed keywords

SURVIVIN;

ALLELE; ARTICLE; ASIAN; BLADDER CANCER; CANCER RISK; COLORECTAL CANCER; DISEASE ASSOCIATION; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HUMAN; KIDNEY CARCINOMA; META ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY ANALYSIS; STOMACH CANCER;

APOPTOSIS; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84898889365     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1229-6     Document Type: Article

References (59)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
2. Pharoah PD, Dunning AM, Ponder BA, Easton DF. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer. 2004;4(11):850-60. (Pubitemid 39472952)
3. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science. 1996;273(5281):1516-7. (Pubitemid 26301653)
4. Mondello C, Scovassi AI. Apoptosis: a way to maintain healthy individuals. Genome stability and human diseases. New York: Springer; 2010. p. 307-23.
5. Raff M. Cell suicide for beginners. Nature. 1998;396(6707):119-19.
6. Ma S, Shen L, Qian N, Chen K. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited. Cancer Biomark. 2011;10(3-4):155-62.
7. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411(6835):342-8. (Pubitemid 32467043)
8. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 1995;267(5203):1456-62.
9. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22(53):8581-9. (Pubitemid 38019195)
10. Wang L, Shao ZM. Cyclin E expression and prognosis in breast cancer patients: a meta-analysis of published studies. Cancer Invest. 2006;24(6):581-7. (Pubitemid 44422921)
11. Xu Y, Fang F, Ludewig G, Jones G, Jones D. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol. 2004;23(9):527-37. (Pubitemid 39244331)
12. Lu D, Qian J, Yin X, Xiao Q, Wang C, Zeng Y. Expression of PTEN and survivin in cervical cancer: promising biological markers for early diagnosis and prognostic evaluation. Br J Biomed Sci. 2012;69(4):143-6.
13. Li XB, Li SN, Yang ZH, Cao L, Duan FL, Sun XW. Polymorphisms of survivin and its protein expression are associated with colorectal cancer susceptibility in Chinese population. DNA Cell Biol. 2013;32(5):236-42.
14. Fawzy A, Gaafar R, Kasem F, Ali SS, Elshafei M, Eldeib M. Importance of serum levels of angiopoietin-2 and survivin biomarkers in non-small cell lung cancer. J Egypt Natl Cancer Inst. 2012;24(1):41-5.
15. Sun YW, Xuan Q, Shu QA, Wu SS, Chen H, Xiao J, et al. Correlation of tumor relapse and elevated expression of survivin and vascular endothelial growth factor in superficial bladder transitional cell carcinoma. Genet Mol Res. 2013;12(2):1045-53.
16. Rosato A, Menin C, Boldrin D, Santa SD, Bonaldi L, Scaini MC, et al. Survivin expression impacts prognostically on NSCLC but not SCLC. Lung Cancer. 2013;79(2):180-6.
17. Wu SF, Zhang JW, Qian WY, Yang YB, Liu Y, Dong Y, et al. Altered expression of survivin, Fas and FasL contributed to cervical cancer development and metastasis. Eur Rev Med Pharmacol Sci. 2012;16(15):2044-50.
18. Zhang LQ, Wang J, Jiang F, Xu L, Liu FY, Yin R. Prognostic value of survivin in patients with non-small cell lung carcinoma: a systematic review with meta-analysis. PLoS One. 2012;7(3):e34100.
19. Radojevic-Skodric S, Basta-Jovanovic G, Brasanac D, Nikolic N, Bogdanovic L, Milicic B, et al. Survivin gene promoter -31 G/C polymorphism is associated with Wilms' tumor susceptibility in Serbian children. J Pediatr Hematol Oncol. 2012;34(8):e310-4.
20. Liarmakopoulos E, Theodoropoulos G, Vaiopoulou A, Rizos S, Aravantinos G, Kouraklis G, et al. Effects of stromal cell-derived factor-1 and survivin gene polymorphisms on gastric cancer risk. Mol Med Rep. 2013;7(3):887-92.
21. Aynaci E, Coskunpinar E, Eren A, Kum O, Oltulu YM, Akkaya N et al. Association between survivin gene promoter -31G/C and -644C/T polymorphisms and non-small cell lung cancer. Genet Mol Res. 2013. doi:10.4238/2013.
22. Marques I, Teixeira AL, Ferreira M, Assis J, Lobo F, Mauricio J, et al. Influence of survivin (BIRC5) and caspase-9 (CASP9) functional polymorphisms in renal cell carcinoma development: a study in a southern European population. Mol Biol Rep. 2013;40(8):4819-26.
23. Weng CJ, Hsieh YH, Chen MK, Tsai CM, Lin CW, Yang SF. Survivin SNP-carcinogen interactions in oral cancer. J Dent Res. 2012;91(4):358-63.
24. Qin C, Cao Q, Li P, Ju X, Wang M, Chen J, et al. Functional promoter -31G>C variant in survivin gene is associated with risk and progression of renal cell cancer in a Chinese population. PLoS One. 2012;7(1):e28829.
25. Yazdani N, Sayahpour FA, Haghpanah V, Amiri P, Shahrabi-Farahani M, Moradi M, et al. Survivin gene polymorphism association with papillary thyroid carcinoma. Pathol Res Pract. 2012;208(2):100-3.
26. Li Y, Wang J, Jiang F, Lin W, Meng W. Association of polymorphisms in survivin gene with the risk of hepatocellular carcinoma in Chinese Han population: a case control study. BMC Med Genet. 2012;13:1.
27. Jaiswal PK, Goel A, Mandhani A, Mittal RD. Functional polymorphisms in promoter survivin gene and its association with susceptibility to bladder cancer in North Indian cohort. Mol Biol Rep. 2012;39(5):5615-21.
28. Hsieh YS, Tsai CM, Yeh CB, Yang SF, Hsieh YH, Weng CJ. Survivin T9809C, an SNP located in 3′-UTR, displays a correlation with the risk and clinicopathological development of hepatocellular carcinoma. Ann Surg Oncol. 2012;19 Suppl 3:S625-33.
29. Zahedi P, Aminimoghaddam S, Sayahpour FA, Haghpanah V, Amiri P, Fereidoni F, et al. Association of survivin gene polymorphismwith endometrial cancer. Int J Gynecol Cancer. 2012;22(1):35-7.
30. Antonacopoulou AG, Floratou K, Bravou V, Kottorou A, Dimitrakopoulos FI, Marousi S, et al. The survivin -31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. Cell Oncol (Dordr). 2011;34(4):381-91.
31. Ma F, Zhang H, Zhai Y, Huang W, Zhao C, Ou S, et al. Functional polymorphism -31C/G in the promoter of BIRC5 gene and risk of nasopharyngeal carcinoma among chinese. PLoS One. 2011;6(2):e16748.
32. Bayram S, Akkiz H, Bekar A, Akgollu E. The association between the survivin -31G/C promoter polymorphism and hepatocellular carcinoma risk in a Turkish population. Cancer Epidemiol. 2011;35(6):555-9.
33. Borges Bdo N, Burbano RR, Harada ML. Survivin -31C/G polymorphism and gastric cancer risk in a Brazilian population. Clin Exp Med. 2011;11(3):189-93.
34. Kawata N, Tsuchiya N, Horikawa Y, Inoue T, Tsuruta H, Maita S, et al. Two survivin polymorphisms are cooperatively associated with bladder cancer susceptibility. Int J Cancer. 2011;129(8):1872-80.
35. Upadhyay R, Khurana R, Kumar S, Ghoshal UC, Mittal B. Role of survivin gene promoter polymorphism (-31G>C) in susceptibility and survival of esophageal cancer in northern India. Ann Surg Oncol. 2011;18(3):880-7.
36. Theodoropoulos GE, Michalopoulos NV, Panoussopoulos SG, Taka S, Gazouli M. Effects of caspase-9 and survivin gene polymorphisms in pancreatic cancer risk and tumor characteristics. Pancreas. 2010;39(7):976-80.
37. Yang X, Xiong G, Chen X, Xu X, Wang K, Fu Y, et al. Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2009;135(10):1341-9.
38. Wang YH, Chiou HY, Lin CT, Hsieh HY, Wu CC, Hsu CD, et al. Association between survivin gene promoter -31 C/G polymorphism and urothelial carcinoma risk in Taiwanese population. Urology. 2009;73(3):670-4.
39. Gazouli M, Tzanakis N, Rallis G, Theodoropoulos G, Papaconstantinou I, Kostakis A, et al. Survivin -31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis. 2009;24(2):145-50.
40. Yang L, Zhu H, Zhou B, Gu H, Yan H, Tang N, et al. The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population. Dig Dis Sci. 2009;54(5):1021-8.
41. Cheng ZJ, Hu LH, Huang SJ. Correlation of -31G/C polymorphisms of survivin promoter to tumorigenesis of gastric carcinoma. Ai Zheng. 2008;27(3):258-63.
42. Jang JS, Kim KM, Kang KH, Choi JE, Lee WK, Kim CH, et al. Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer. 2008;60(1):31-9. (Pubitemid 351434465)
43. Borbely AA, Murvai M, Szarka K, Konya J, Gergely L, Hernadi Z, et al. Survivin promoter polymorphismand cervical carcinogenesis. J Clin Pathol. 2007;60(3):303-6. (Pubitemid 46447748)
44. Wang X, Huang L, Xu Y, Shi Z, Wang Y, Zhang J, et al. Association between survivin -31G>C promoter polymorphism and cancer risk: a meta-analysis. Eur J Hum Genet. 2012;20(7):790-5.
45. Srivastava K, Srivastava A, Mittal B. Survivin promoter -31G/C (rs9904341) polymorphism and cancer susceptibility: a meta-analysis. Mol Biol Rep. 2012;39(2):1509-16.
46. Guo SW, Thompson EA. Performing the exact test of Hardy-Weinberg proportion for multiple alleles. Biometrics. 1992;48(2):361-72.
47. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127(9):820-6. (Pubitemid 27465551)
48. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-88. (Pubitemid 17189972)
49. Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med. 1991;10(11):1665-77.
50. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-34. (Pubitemid 27387172)
51. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3(8):917-21. (Pubitemid 27353455)
52. Deveraux QL, Reed JC. IAP family proteins - suppressors of apoptosis. Genes Dev. 1999;13(3):239-52. (Pubitemid 29095796)
53. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396(6711):580-4. (Pubitemid 28563719)
54. Altieri DC. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med. 2001;7(12):542-7. (Pubitemid 33127139)
55. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006;5(5):1087-98. (Pubitemid 43881300)
56. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 2002;277(5):3247-57. (Pubitemid 34953189)
57. Mityaev MV, Kopantzev EP, Buzdin AA, Vinogradova TV, Sverdlov ED. Functional significance of a putative sp1 transcription factor binding site in the survivin gene promoter. Biochemistry (Mosc). 2008;73(11):1183-91.
58. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med. 2002;4(2):45-61. (Pubitemid 44698579)
59. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004;96(6):434-42. (Pubitemid 38443646)